Skip to main content

23andMe Closes on $22M Series C Funding

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – 23andMe today said that it has closed on its Series C financing, raising more than $22 million.

New investor Johnson & Johnson Development Corp. participated in the round, which also included New Enterprise Associates and Google Ventures, the Mountain View, Calif.-based personal genetics testing firm said in a statement.

"We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research and could ultimately make healthcare research and healthcare delivery more efficient," Anne Wojcicki, CEO of 23andMe, said in a statement.

In June last year, the company received $2.6 million in a Series B investment from Google. It also invested $3.9 million into 23andMe in 2007 to help the company launch.

In addition, 23andMe said that it has a number of key positions open that it is looking to fill. A year ago, the firm laid off staff in response to the economy and to remain competitive.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.